Frontier Wealth Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Frontier Wealth Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,809	Closed	-$583K	–	419
2016 Q3	$583K	Buy	3,809 +1,556	+69%	+$220K	0.09%	188
2016 Q2	$259K	Sell	2,253 -74	-3%	-$8.2K	0.04%	293
2016 Q1	$264K	Sell	2,327 -187	-7%	-$28.3K	0.02%	270
2015 Q4	$474K	Sell	2,514 -124	-5%	-$23.2K	0.08%	204
2015 Q3	$449K	Buy	2,638 +1,005	+62%	+$363K	0.07%	217
2015 Q2	$1.03M	Buy	+1,633	New	+$868K	0.16%	127

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Frontier Wealth Management's VIRX Position: Q4 2016 in Review

Frontier Wealth Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2016, closing a stake of 3,809 shares — an estimated $583K sold.

Frontier Wealth Management first reported a position in VIRX in Q2 2015 and held it in 6 quarters. The position peaked at $1.03M in Q2 2015. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

Frontier Wealth Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Frontier Wealth Management sold 3,809 Viracta Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $583K.
Frontier Wealth Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
Frontier Wealth Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.03M in Q2 2015.
45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Frontier Wealth Management's 13F filing for Q4 2016, filed 10 Feb 2017.